KPIs & Operating Metrics(New)
Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios
Asset Utilization RatioAssets AverageEBIT MarginEBITDA MarginEBT MarginEnterprise ValueEquity AverageEquity RatioFCF MarginGross MarginInterest Coverage RatioInventory AverageInvested CapitalNet MarginOperating MarginReturn on AssetsReturn on Capital EmployedReturn on EquityReturn on Invested CapitalReturn on SalesTimes Interest Earned

Biomarin Pharmaceutical (BMRN) FCF Margin (2017 - 2025)

Biomarin Pharmaceutical's FCF Margin history spans 16 years, with the latest figure at 6.74% for Q4 2025.

  • For the quarter ending Q4 2025, FCF Margin fell 1549.0% year-over-year to 6.74%, compared with a TTM value of 22.51% through Dec 2025, up 543.0%, and an annual FY2025 reading of 22.51%, up 543.0% over the prior year.
  • FCF Margin for Q4 2025 was 6.74% at Biomarin Pharmaceutical, down from 43.84% in the prior quarter.
  • The five-year high for FCF Margin was 43.84% in Q3 2025, with the low at 16.5% in Q1 2023.
  • Average FCF Margin over 5 years is 11.31%, with a median of 12.84% recorded in 2021.
  • Year-over-year, FCF Margin surged 2921bps in 2021 and then crashed -3240bps in 2022.
  • Tracing BMRN's FCF Margin over 5 years: stood at 3.9% in 2021, then crashed by -38bps to 5.38% in 2022, then skyrocketed by 96bps to 0.22% in 2023, then skyrocketed by 10116bps to 22.23% in 2024, then plummeted by -70bps to 6.74% in 2025.
  • Per Business Quant, the three most recent readings for BMRN's FCF Margin are 6.74% (Q4 2025), 43.84% (Q3 2025), and 20.37% (Q2 2025).